Respiratory syncytial virus bronchiolitis

3 trials MedDRA PT
3 Registered trials
0 Recruiting
2 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
N Neurology/Psychiatry (ATC N) 2
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Monoclonal antibody (antiviral) 1 substance
Phase III: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

3 trials
  • GlaxoSmithKline Biologicals Commercial
    RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-FUSION CONFORMATION, ADJUVANTED WITH AS01E
    2023-509762-38-00 7 countries 2024 n=4,918
    Ended
  • GlaxoSmithKline Biologicals Commercial
    RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-FUSION CONFORMATION, ADJUVANTED WITH AS01E
    2023-510190-34-00 1 country 2024 n=70
    Ended
  • Azienda Sanitaria Locale Della Provincia Di Biella Academic
    PALIVIZUMAB
    2024-515418-41-00 1 country 2020 n=760
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
GlaxoSmithKline Biologicals Commercial 2 Phase III 0
Azienda Sanitaria Locale Della Provincia Di Biella Academic 1 Phase III 0
New trials by year
2020
1
2024
2
← All indication landscapes